Categories AlphaGraphs, Earnings

Quest Diagnostics reports Q1 revenue of $1.88 billion, up 3.7%.

Quest Diagnostics (DGX) reported positive top and bottom line results for its first quarter, with revenue increasing to $1.88 billion, up 3.7%, driven by strategic acquisitions and lower Medicare reimbursement under PAMA (Protecting Access to Medicare Act).

Net income was boosted by benefits from tax reforms and revenue increase, pushing it up 8.2% year-over-year to $177 million. EPS on a reported basis increased 9.5% to $1.27, while on an adjusted basis, EPS spiked 24.6% to $1.52 per share.

The company topped on analysts’ earnings estimates, while missed on revenue expectation. The positive results were also driven by higher requisition volumes, which increased 2.2% from the prior year.

For fiscal year 2018, Quest has kept its earlier guidance unchanged and sees revenue in the range of $7.70 billion to $7.77 billion, an increase of 4% to 5% year-over-year. Reported earnings, on a per share basis, is expected in the range of $5.42 to $5.62, while adjusted EPS is forecast to be in the range of $6.50 to $6.70. The guidance reflects the impact of new revenue recognition rules that are effective January 1, 2018.

DGX stock almost dipped 1% post earnings announcement in pre-market trading.

Quest Diagnostics Q1 2018 Earnings
Quest Diagnostics Q1 2018 Earnings Infographic

The Madison, New Jersey-based company has a long-term revenue growth target of 3% to 5% that it is progressing with the help of its two-prong approach of strategic acquisitions and operational excellence. In line with its progress, the company completed two key acquisitions in the recent past of Cleveland HeartLab and Mobile Medical Examination Service MedXM, which contributed to the positive results.

Most Popular

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Walgreens Boots Alliance set to report earnings next week. Here’s what to expect

Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top